Verapamil prevents posttransplant delayed function and cyclosporine A nephrotoxicity.
I
I
Dawidson
P
P
Rooth
C
C
Alway
T
T
Dulzo
B
B
Palmer
C
C
Lu
P
P
Peters
A
A
Sagalowsky
Z
Z
Sandor
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D016030:Kidney Transplantation / Q000473:pathology / Q000502:physiology*; D008875:Middle Aged; D011897:Random Allocation; D012079:Renal Circulation; D014700:Verapamil / Q000627:therapeutic use*
D000961:Antilymphocyte Serum; D003524:Cyclosporins; D014700:Verapamil